Lisanti Capital Growth LLC Makes New Investment in Palvella Therapeutics, Inc. $PVLA

Lisanti Capital Growth LLC acquired a new position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 41,470 shares of the company’s stock, valued at approximately $4,341,000. Lisanti Capital Growth LLC owned about 0.35% of Palvella Therapeutics at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Legato Capital Management LLC bought a new stake in Palvella Therapeutics during the fourth quarter worth about $1,192,000. PSP Research LLC bought a new stake in Palvella Therapeutics during the fourth quarter worth about $532,000. Profund Advisors LLC bought a new stake in Palvella Therapeutics during the fourth quarter worth about $608,000. Baader Bank Aktiengesellschaft bought a new stake in Palvella Therapeutics during the fourth quarter worth about $326,000. Finally, Chung Wu Investment Group LLC grew its stake in Palvella Therapeutics by 1,200.0% during the fourth quarter. Chung Wu Investment Group LLC now owns 2,600 shares of the company’s stock worth $272,000 after buying an additional 2,400 shares during the last quarter. 40.11% of the stock is owned by institutional investors.

Insider Activity at Palvella Therapeutics

In other Palvella Therapeutics news, Director Elaine J. Heron acquired 2,400 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The shares were acquired at an average cost of $125.00 per share, for a total transaction of $300,000.00. Following the completion of the acquisition, the director directly owned 47,812 shares of the company’s stock, valued at approximately $5,976,500. This represents a 5.28% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The SEC filing for this sale provides additional information. 20.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

PVLA has been the topic of several research analyst reports. Wall Street Zen cut shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. HC Wainwright increased their price target on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. BTIG Research increased their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Finally, Chardan Capital reissued a “buy” rating and set a $240.00 price target on shares of Palvella Therapeutics in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Price Performance

Shares of NASDAQ PVLA opened at $113.99 on Friday. The company’s 50 day simple moving average is $121.93 and its 200 day simple moving average is $105.45. Palvella Therapeutics, Inc. has a fifty-two week low of $20.20 and a fifty-two week high of $151.18. The firm has a market capitalization of $1.63 billion, a P/E ratio of -27.34 and a beta of -0.13.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Sell-side analysts expect that Palvella Therapeutics, Inc. will post -5.43 EPS for the current fiscal year.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.